Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm.

Cureus·2026
Same author

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

Research square·2026
Same author

A novel role of secreted methionine adenosyltransferase α2 in colorectal liver metastases.

Journal of experimental & clinical cancer research : CR·2025
Same author

Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring.

Precision chemistry·2025
Same author

Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment.

Cureus·2025
Same author

Strength, weakness, opportunities and challenges (SWOC) experience of histopathology image analysis, enhanced by artificial intelligence.

Journal of oral biology and craniofacial research·2025

Related Experiment Video

Updated: Dec 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next

Jacob J Adashek1, Jarred P Reed2, Ankita Tandon1

  • 1Department of Internal Medicine, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Clinical Genitourinary Cancer
|July 8, 2020
PubMed
Summary

New treatments combining androgen deprivation therapy (ADT) with docetaxel, abiraterone, enzalutamide, or apalutamide are now standard for metastatic castration-sensitive prostate cancer (mCSPC). Triplet and maintenance strategies show promise.

Keywords:
Androgen inhibitionCastration-sensitiveDocetaxelProstate cancer

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.8K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.8K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Area of Science:

  • Oncology
  • Urology

Background:

  • Metastatic castration-sensitive prostate cancer (mCSPC) treatment has evolved significantly.
  • Androgen deprivation therapy (ADT) combined with docetaxel or abiraterone became a new standard.
  • Recent trials introduced enzalutamide and apalutamide, further advancing first-line mCSPC care.

Purpose of the Study:

  • To review the impact of novel agents in first-line mCSPC treatment.
  • To contextualize the findings of recent trials involving enzalutamide and apalutamide.
  • To explore emerging triplet and maintenance strategies in mCSPC.

Main Methods:

  • Review of seminal clinical trials in first-line mCSPC.
  • Analysis of data from trials investigating docetaxel, abiraterone, enzalutamide, and apalutamide.
  • Discussion of treatment implications and current landscape.

Main Results:

  • Docetaxel, abiraterone, enzalutamide, and apalutamide combined with ADT are established first-line standards for mCSPC.
  • Recent trials confirm the efficacy of enzalutamide and apalutamide in this setting.
  • Preliminary data suggest potential benefits of triplet and maintenance strategies.

Conclusions:

  • The combination of ADT with docetaxel, abiraterone, enzalutamide, or apalutamide represents the current standard of care for first-line mCSPC.
  • Ongoing research into triplet and maintenance regimens offers promising future directions for mCSPC management.